RePORT International Highlights

Registration is open. This workshop gathers top researchers from across the world, who will provide in-depth understanding of both practical and theoretical concepts of bioinformatics. Participants will be equipped to address bioinformatics questions and offer insight to peers and society, advancing the field and improving public health. September 6-11, 2026, Stellenbosch, South Africa

The 5th International Conference on Public Health in Africa (CPHIA 2026) will be held from 1–5 November 2026 in Addis Ababa, Ethiopia. Co-hosted by the Africa Centres for Disease Control and Prevention (Africa CDC) and the Government of Ethiopia, this conference will bring together political leaders, policymakers, researchers, innovators, civil society, and youth. Participants will work to define Africa’s pathway to stronger, more resilient health systems and to reducing dependence on foreign aid.

Advancing Military and Civilian Medical Research Including Military Infectious Diseases Research Program Closing Date: Sep 30, 2027

LOI DEADLINE: 16 July 2026 FULL PROPOSAL SUBMISSION: 2 October 2026 The Investigators in the Pathogenesis of Infectious Disease (PATH) program provides opportunities for assistant professors to bring multidisciplinary approaches to studying human infectious diseases. The program aims to provide accomplished investigators at the assistant professor level with opportunities to study what happens at the points where the systems of humans and potentially infectious agents connect. The program supports research that sheds light on the fundamentals that affect the outcomes of these encounters: how colonization, infection, commensalism, and other relationships play out at levels ranging from molecular interactions to systemic ones. PATH is a highly competitive award program that provides $505,000 over five years to study pathogenesis. The program intends to give recipients the freedom and flexibility to pursue new avenues of inquiry, stimulating higher-risk research projects that hold potential for significantly advancing our understanding of how infectious diseases work and how health is maintained.

Global Health EDCTP3 has opened the calls for abstracts, scientific symposia and workshops for the EDCTP Forum 2027, one of the leading global health research events focused on infectious diseases in sub-Saharan Africa. The deadline for submissions is 2 September 2026 at 17:00 (Brussels time). Under the theme ‘Innovating together for resilient global health', the 13th edition of the EDCTP Forum, taking place from 5-9 April 2027 in Madrid, Spain, will offer researchers, policymakers, funders and implementers the opportunity to showcase their work at a flagship global health event. The Forum offers a unique platform to share research findings, build partnerships and help shape discussions on global health priorities. Currently, submissions for abstracts, scientific symposia and workshops are open. Please refer to the detials on the website

Applications are now open for the EDCTP Prizes 2027, recognising outstanding individuals and research teams from Africa and Europe for their achievements in global health research and innovation. The 2027 edition will award four prize categories, highlighting excellence in scientific leadership, collaborative team research, and gender-balanced scientific contribution. Please refer to the website for the details. How to apply Eligibility criteria and application requirements are available in the Rules of Contest. Applications must be submitted directly by the individuals or teams applying for the prizes through the Funding and Tenders Portal and should include letter(s) of recommendation from at least one reputable scientist. The deadline for applications is 2 September 2026 at 17:00 (Brussels time).

The ERC plans to launch the grant competitions under its 2027 Work Programme between July 2026 and June 2027, with the calls for proposals introducing several changes to the eligibility rules for applications. Please refer to the website for the details.

Deadline: 14 August 2026 The GHIT Fund announces the Request for Proposals (RFP) for the Hit-to-Lead Platform (HTLP). The Hit-to-Lead Platform (HTLP) leverages the medicinal chemistry expertise in Japan and facilitates access to relevant and diverse compounds to address the unmet needs of the following diseases. - Malaria - Tuberculosis - Chagas Disease - Schistosomiasis - Viral Infectious Diseases with Pandemic Potential HTLP focuses on the aspect of the drug discovery and development process that advances hits, identified through compound library screening, into lead compounds that can then be optimized into drug candidates. This platform will provide a bridge from early drug discovery to GHIT’s Product Development Platform that begins with the lead-optimization step. The key requirement of the Hit-to-Lead Platform is to convert drug hits derived from Japanese compound libraries or hits identified using innovative Japanese technologies into lead series through a comprehensive assessment of chemical integrity, synthetic accessibility, scalability and novelty, functional behavior, and structure-activity relationships (SAR), as well as bio-physiochemical and absorption, distribution, metabolism and excretion (ADME) properties. Interested applicants can find detailed information on the website

Global Health EDCTP3 has launched its 2026 Work Programme, which includes six calls for proposals to support research and innovation projects addressing tuberculosis, lower respiratory tract infections, HIV, climate-change-driven infectious diseases and other pressing global health challenges. The calls for proposals will open for submission by mid-January 2026. To support interested applicants, an online Info Day will be held on 5 February 2026. During the event, participants will receive detailed information on the call topics, application process and evaluation criteria. Please refer to the webiste for the key dates and details.

MULTIPLE DEADLINES Please refer to the website for the details Global Health EDCTP3 invests in global health through funding collaborative research and innovation projects tackling infectious diseases and supporting activities for research capacity building in Africa. Check the website for detailed information on the calls for proposals.

CONFERENCE DATE: 26-31 July 2026; LOCATION: Rio de Janeiro, Brazil and virtually Please refer to the website for the details.

Abstract Submission Deadline: August 21st, 2026 We are pleased to announce that the 16th edition of the International Workshop on Clinical Pharmacology of Tuberculosis Drugs will take place October 14-15, 2026, as a virtual meeting. This abstract-driven workshop has been a leading annual meeting in the field of tuberculosis (TB) pharmacology since 2008. The aim of the meeting is to contribute to the optimization of TB treatment by providing an independent platform for the presentation and discussion of the latest scientific developments in TB pharmacology. If you work in TB, you are invited to join us. This includes preclinical and clinical pharmacology researchers from academia and industry; medical doctors, pharmacists, and pharmacologists involved in clinical management of TB patients; laboratorians, nurses, and PhD students; and representatives from regulatory or non-governmental organizations active in the TB field. The program consists of oral presentations that will be put in perspective, with a translation to clinical care where possible, by selected experts at the end of each workshop session. In addition, there will be e-poster abstract presentations. The workshop is informal in setting and is meant to be interactive.

Grants Deadline AT MIDNIGHT CST Spring: February 1 - March 31 Fall: August 1 - September 30 The Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation is seeking highly innovative and groundbreaking medical research proposals in both basic biological and applied research that will have the greatest impact on scientific knowledge and human health. The Foundation focuses on basic science and some translational - not clinical - research. All applications must be approved by the University Provost or the Vice President of Research, and should be submitted through the office of sponsored research or like office that provides institutional approval for the request. Studies selected through an internal competition are preferred. Applications submitted by an individual researcher will NOT be considered.

Grant schedules and submission deadlines are fixed annually. (Spring and Fall cycles) The Mathers Foundation supports basic research with translational potential in areas such as immunology, microbiome, structural biology, cancer, genetics, stem cells, and neuroscience. We fund work that can lead to major advances in scientific understanding and human health. Please refer to the website for the details.

Conference takes place October 14-16, 2026 in Manipal, India. Registration now open! Organized in partnership by Nature Medicine, Nature Microbiology, Nature Health, Nature Communications, and MAHE, this conference will bring together leading voices in infectious disease research to explore innovative solutions to global health challenges. As the world faces rising threats from emerging pathogens, climate change, and antimicrobial resistance, the event will highlight advances in surveillance, diagnostics, drug development, and vaccination strategies. Program highlights include: Disease surveillance, modelling and forecasting Antimicrobial resistance and drug development Challenges in diagnostic and screening Disease prevention strategies Future of vaccination and disease eradication Climate change and One Health approaches Pandemic preparedness

Background: Conversational chatbots are increasingly integrated into daily life, including in health-related information-seeking, decision support, social interaction, and informal caregiving contexts. These systems are now used by individuals to interpret symptoms, manage chronic conditions, make financial and health decisions, and mitigate social isolation, often without professional oversight. Use of chatbot technologies is expanding rapidly, and patterns of adoption, benefit, and risk are likely to differ across populations, contexts, and system designs. At present, there is insufficient evidence regarding the benefits and harms of chatbot use for health and well-being or to characterize unintended consequences such as misinformation, over-reliance, altered decision-making, or delayed engagement with professional care. Rigorous research is needed to understand how chatbot design (including potential built-in safeguards), chatbot use (including but not limited to context and frequency of use), and user characteristics interact to shape health-relevant outcomes. Efforts should inform safeguards, standards, and evidence-based guidance. Purpose: This topic encourages multidisciplinary research that identifies, measures, and explains the benefits and harms associated with chatbot use (both chatbot-based interventions or treatments and routine chatbot use) across a variety of populations, use cases, and settings. Of interest are studies that move beyond proof-of-concept to characterize mechanisms, safety, and impacts on behavior, decision-making, and health outcomes. Of particular interest are studies that: - Identify risk mechanisms: including automation bias, persuasive effects, misinformation exposure, behavioral dependency, and substitution for professional care, and document adverse outcomes across different chatbot designs, and health or wellbeing-related purposes. - Compare safety and performance across chatbot models, including adaptive versus static designs and varying degrees of personalization, information retrieval, or relational engagement. - Examine impacts on decision-making and autonomy: including how chatbot use influences judgment, independence, help-seeking behavior, and relationships with family, caregivers, and clinicians. - Characterize health and functional outcomes associated with patterns of use: including frequency, duration, and longitudinal engagement, with attention to cognitive, emotional, social, and behavioral consequences. - Develop and test safeguards: including monitoring strategies and design features that promote safe, ethical, secure, and beneficial use, particularly for populations at elevated risk of harm. - Ideally, studies will focus on advancing understanding of causal mechanisms driving observed or hypothesized effects and emphasize methodological rigor, appropriate comparators, and real-world relevance.

The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Notice of Funding Opportunity Announcement requires that at lease 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Fogarty's new webpage 'NIH Support of International Research: Navigating NIH Public Resources' website page contains useful information for researchers. Alongside links to NIH Guide Notices and NIH extramural news resources, the page offers guidance on the newly published application and award structure for applications that request funding for international organizations (the PA-26-002 NIH Collaborative International Research Project--Parent PF5 Clinical Trial Optional).

Funding Opportunity Purpose: The purpose of this notice of funding opportunity (NOFO) is to support innovative basic, clinical, translational, and implementation science research relevant to HIV and substance use. This initiative encourages high risk high impact transformative studies that advance knowledge and strategies for HIV prevention, diagnosis, treatment and virus suppression in people who use substances and/or have a substance use disorder. Funding Opportunity Goal(s): To support basic, clinical, translational, and implementation research in the field of substance use. To develop new knowledge and approaches for the prevention, diagnosis, and treatment of drug use, misuse, and addiction, drug overdose, and related health outcome, including HIV/AIDS. Application due date: Multiple dates, see announcement.

Application due date: Multiple dates, see announcement